Daniel Zielonka

The influence of gender on phenotype and disease progression in patients with Huntington's disease

Daniel Zielonka, Johan Marinus, Raymund A.C. Roos et al. · Parkinsonism & Related Disorders · 2012 · 114 citations

Disease Progression, Genetic Disorder, Genetics +5

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Ralf Reilmann, Andrew McGarry, Igor D. Grachev et al. · The Lancet Neurology · 2018 · 104 citations

Neurodegenerative Diseases, Medicine, Psychotropic Medication +6

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease

Daniel Zielonka, Michał Ren, Giuseppe De Michele et al. · Parkinsonism & Related Disorders · 2018 · 55 citations

Neuropsychological Functioning, Neurological Functioning, Cognitive Features +8

Clinical manifestations of intermediate allele carriers in Huntington disease

Esther Cubo, María A. Ramos-Arroyo, Saül Martínez‐Horta et al. · Neurology · 2016 · 53 citations

Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke.

Agnieszka Adamczak-Ratajczak, Justyna Kupsz, Michał K. Owecki et al. · PubMed · 2017 · 42 citations

Neurophysiological Biomarkers, Neurochemical Biomarkers, Social Sciences +17